Pegvaliase is an enzyme used to treat phenylketonuria in patients with phenylalanine levels that are too high on current treatment. Pegvaliase is a recombinant phenylalanine ammonia lyase (PAL) enzyme derived from Anabaena variabilis that converts phenylalanine to ammonia and trans-cinnamic acid.
- Mechanism
- Curator reviewed · 2 references
Pegvaliase is a phenylalanine ammonia lyase (PAL) enzyme that temporarily restores the levels of deficient enzyme and reduces blood phenylalanine concentrations by converting phenylalanine to ammonia and trans-cinnamic acid. Formed conversion products are metabolized in the liver and later excreted in the urine.
- Primary indication
- Pegvaliase is indicated for the management of phenylketonuria (PKU) in adult patients who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.Curator reviewed · 3 structured indications
- First approval
- Canada, 2022 · United States, 2018 · European Union, 2021
- Also known as
- PEG PAL · PEG-PAL · pegvaliase-pqpz · Phenylase · rAvPAL-PEG
- Code names
- BMN-165
- Brand names
Resolves to
What you can answer from here — as of September 13, 2026
Which drugs share a target with Pegvaliase, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account